Rochester Institute of Technology

RIT Scholar Works
Theses
5-8-2019

Using the Diels-Alder Reaction in the Synthesis of Biologically
Interesting Molecules: Targets of Opportunity
Ethan Michael DeCicco
emd4967@rit.edu

Follow this and additional works at: https://scholarworks.rit.edu/theses

Recommended Citation
DeCicco, Ethan Michael, "Using the Diels-Alder Reaction in the Synthesis of Biologically Interesting
Molecules: Targets of Opportunity" (2019). Thesis. Rochester Institute of Technology. Accessed from

This Thesis is brought to you for free and open access by RIT Scholar Works. It has been accepted for inclusion in
Theses by an authorized administrator of RIT Scholar Works. For more information, please contact
ritscholarworks@rit.edu.

Using the Diels-Alder Reaction in the Synthesis of Biologically Interesting Molecules:
Targets of Opportunity

Ethan Michael DeCicco

Submitted in Partial Fulfillment
of the
Requirements for the Degree
Master of Science in Chemistry

Supervised by
Jeremy A. Cody

School of Chemistry and Material Science
College of Science
Rochester Institute of Technology
Rochester, NY

May 8th, 2019

i

Thesis Committee and School Approval:

May 16, 2019
Dr. Jeremy A. Cody

Date

Thesis Advisor

May 14, 2019
Dr. Christina Goudreau Collison

Date

Committee Member

May 9, 2019
Dr. Douglas J. Tusch

Date

Committee Member

May 9, 2019
Dr. Michael G. Coleman

Date

Committee Member, Director of Chemistry MS Program

ii

Acknowledgements
First, I would like to thank my advisor, Dr. Jeremy Cody, for his patience, guidance and wisdom
during my time at Rochester Institute of Technology. Dr. Cody has facilitated my improvement
in every aspect of organic synthesis, to a degree I would not have thought possible in such a
short time. I have him to thank for a truly irreplaceable research experience and will remember
his many lessons in all my future endeavors.
I owe a great deal of gratitude to my committee members, Dr. Christina Goudreau Collison, Dr.
Michael Coleman and Dr. Douglas Tusch. Their advice, guidance and helpful discussion has
helped me develop not only in research, but also as a teacher and student.
I would like to thank Dr. Andre Hudson and Dr. Michael Gleghorn for their collaboration that
provided key information for this project. Gratitude is also due to Dr. Jeff Mills for his generous
assistance in spectroscopy experiments.
To my past and present co-workers, Michael Grant, Rob Makar, Allen Snyder, Becky Bogart,
Jordan McNaughton, Jenn Swartzenberg, Jordan Dejewski and Molly McMahon, I thank you all
for helpful discussion and unforgettable comradery.
Special thanks are due to Mr. Dejewski, whose computational work in this project has provided
valuable information and an indispensable asset to the Cody group.
Finally, I would like to thank my loving girlfriend Lindsey, my parents Michael and Debby and
my sisters Caitlyn and Ashleigh. I owe all my success to their constant encouragement, love and
support.

iii

Abstract
This thesis is composed of reports on two projects, which are described separately in two
chapters.
The first project described (Chapter 1) involves the synthesis of a series of molecules that
contain a 1,4-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxy-imide core structure. These
types of molecules represent a class of analogues of the natural product cantharidin, a potent
cytotoxic agent isolated from Meloidae insects. Cantharidin and cantharidin-like small molecules
have been extensively studied in literature as potential leads in new anti-cancer medications. A
series of 1,4-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3- dicarboxy-imides are also being
investigated by researchers at Bristol-Meyers-Squibb (BMS) as prospective treatments of
prostate cancer (PC). PC is the most common malignancy among men in the United States and
the second most common cause of cancer-related death worldwide. The need for novel prostate
cancer medications arises from patient resistance to current PC drugs. Synthesis and biological
activity of a series of cantharidin/BMS-641988 analogues will be presented. Theoretical studies
to identify our next generation of synthetic targets and their potential application in the treatment
of PC will also be discussed.
The second project (Chapter 2) describes new methodology studies to provide access to 9membered lactones. This structural moiety is an unusual, yet frequently observed structural
feature of natural products. The synthesis of medium sized cyclic functional groups, namely 9membered lactones, is still a formidable challenge in synthetic organic chemistry. Studies toward
a facile, three step synthesis of molecules containing 9-membered lactones is proposed and
synthetic efforts towards the appropriate precursors will be discussed.
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Chapter 1- Synthesis of Cantharidin Based Molecules for the
Discovery of New Bioactive Compounds
1- Introduction
1.1- Natural Products as Source of New Medicine
Natural products (NPs) is a term used to describe substances produced by and then
isolated from all forms of life, including marine organisms, bacteria, fungi, insects and plants1
and possess enormous structural and chemical diversity2. Molecules produced by biological
entities naturally have a key role in drug discovery. NPs still prove to be a reliable source of new
drugs, drug targets and bioactive structures3. Accordingly, 50% of FDA approved drugs from
1981 to 2010 were natural product derived, synthetically made based on a NP skeleton or NPs
themselves, where only 29% were purely synthetic based on targets from screening and the
remainder were either biologic treatments or vaccines3. Combinatorial chemistry is often
employed in the discovery of new drugs, however, only one de novo discovery from
combinatorial techniques has led to an FDA approved drug from 1981-20123. Further, of the 175
small molecule cancer treatments approved since the 1940s, 74.8% are other than purely
synthetic and 48.6% are either directly NPs or NP derived3. The antibacterial field shows a heavy
reliance on natural products for new drugs. In the same period, 65% of new antibacterial drugs
were NPs, NP based, or synthesized base on NP pharmacophore3. Only 14% of new antibiotics
were produced based on screening or rational design, and the remainder were either biologic
treatments or vaccines3. Deriving drugs from NPs shows advantages statistically vs.
combinatorial chemistry or screening approaches. Despite showing advantages as a source for
new drugs against classical techniques, other factors of drug development make them more
attractive.
1

A desirable prospect in drug development is the possibility of oral drug delivery. The
convenience of oral delivery makes it the most attractive form of drug delivery, opposed to
intravenous injections and other invasive methods. The seminal work published by Lipinski in
2004 established four properties a drug target should possess for the eventual possibility of oral
drug delivery4. This is known as Lipinski’s (or Pfizer’s) rule of five4. The first four rules denote
that in order to be developed to an orally available drug, a drug target must: 1. Have no more
than five hydrogen bond donors, 2. Have no more than ten hydrogen bond acceptors, 3. Have a
molecular weight of less than 500amu and 4. Have a octanol-water partition coefficient less than
five (log P=5)4, describing the necessity for hydrophilicity. These limitations would serve to
eliminate a large list of target molecules because their inability to be delivered orally. However,
Lipinski’s 5th rule states that the first four do not apply to natural products or those involved in
active transport when considering “druggable chemical entities,”4. A “druggable chemical
entity,” is one that has enough “druglikeness,” to be developed into an orally active drug. Thus,
natural products and natural product like targets can be considered viable drug targets for oral
delivery by the inherent nature of their active transport within the biological systems.
Fungi, lichens, bacteria, insects other microbial organisms are key sources of natural
products5,6. Because these organisms have no phenotypic modes of defense, they have evolved to
synthesize toxic molecules for defense. Such toxic molecules can be isolated and tailored for
benefit. The vast degree of biological diversity that exists in environments where NPs are usually
found (forests, soils and oceans) require considerable time and resources to isolate and identify
new molecules.
Searching for new naturally occurring molecules has classically targeted fungi, plants,
baceteria and marine organisms5. Indeed, commonly known drugs today owe their origin of
2

discovery to nature. The first and most commonly used antibiotic Penicillin was first isolated
from the fungus Penicillum notatum by Alexander Fleming in 1828, later shown to be a powerful
antibiotic by Howard Florey and Ernst Chain7. The total synthesis of Penicillin by John Sheehan
in 1958 allowed for development of more antibiotic analogues8. Aspirin owes its development to
the historical use of willow bark extracts to treat inflammation and the isolation of the active
ingredient by Henri Leroux in the 1890s7. Streptomycin, the first successful treatment for
Tuberculosis, was first isolated from the soil bacterium Streptomyces griseus in 1943 by Selman
Waksman, Albert Schatz, and Elizabeth Bugie9. Halichondrin B is an anti-tumor macrolide
discovered from marine sponge Halichondria okadai by Yoshimasa Hirata and Daisuke Uemura
in 198310. Total synthesis of halichondrin B by Thomas Aicher in 1992 led to development of the
analogue Eribulin mesylate (Halaven®), currently used in the treatment of metastatic breast
cancer11. Even with these invaluable contributions to medicine there has been an emerging focus
on insects as a source of new natural products.

3

1.2- Insects as Source of New Natural Products – Cantharidin 1

Figure 1- Structure of cantharidin (1) (top) isolated from Lytta vesicatoria. Structures of
naturally occurring analogues 2-612. Photo: Wikimedia Commons13
For as long as plants and fungi have been used medicinally, the use of insects to treat
disease (entomotherapy) has occurred for just as long6. In some underdeveloped regions of the
world entomotherapy is still a common practice6. Historical interest in isolating natural products
from insects shown is in the successful isolation of small molecules with varying bioactivity
from ants, sawflies, beetles, cockroaches, grasshoppers, butterflies and moths in the modern era6.
Further, over one hundred new natural products have been isolated from insects in the past
decade6. A notable source of new molecules comes from organisms of the Coleoptera order
(beetles). Among them are the Meloidae, a small group of an estimated 2500 species whose
secretions can cause skin irritation and blistering12, colloquially known as blister beetles6. Their
historical use as therapeutic agents dates to 13th century China in wart removal and anti-cancer
therapy in Middle Ages Europe6. The ‘spanish fly’ (Lytta vesicatoria), when under stress
secretes a toxic hemolymph (analogous to mammalian blood) as a mode of chemical defense12.

4

This phenomenon interested French pharmacist Pierre Jean Robiquet, who in 1838 isolated a
crystalline compound from the dried and ground beetles, known today as cantharidin (1)
(exo,exo-1,4-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid anhydride) (Figure 1)12.
A demthylated analogue, known as (-)-palosonin 2 and its enantiomer 3 (Figure 1), has been
isolated from seeds of the Himalayan plant Butea frondosa and is present in dried bodies of
African beetles Hycleus oculatus and Hycleus tinctus12. Other notable analogues also found in
nature include norcantharidin (4), cantharimide (5) and norcantharimide (6).
1.3- Previous Syntheses of Cantharidin and Utility of Diels-Alder Reactions
Cantharidin historically gained notoriety as the ‘spanish fly’ aphrodisiac. Conversely,
synthetic efforts toward cantharidin and structurally similar small molecules generated
compounds shown to exhibit anti-tumor qualities across a variety of cell lines in 196314. It later
was shown the anti-tumor activity results from strong inhibition of protein phosphatases15,16,
calling for analogues that possessed selective toxicity while minimizing acute toxicity.

Scheme 1- Early proposed route to cantharidin (1) by Otto Diels and Kurt Alder17,18.
The simple structure of cantharidin calls for the obvious but optimal synthetic route of a
Diels-Alder reaction of dimethyl-maleic anhydride (7) and furan (8), which was proposed as
early as 1929 by Otto Diels and Kurt Alder themselves17 (Scheme 1). The first synthesis attempts
through this Diels-Alder reaction failed inexplicably. Rationale came later in the 1950s from
Fukui and his molecular orbital considerations of conjugated systems, known today as frontier

5

molecular orbital (FMO) theory19. The lack of reaction between furan (8) and anhydride 7 was
circumvented in 1951 by Gilbert Stork and his co-workers20 achieving the first total synthesis of
cantharidin (1) in poor overall yield (0.5% overall) (Scheme 2).

Scheme 2- First enantioselective synthesis from Stork et al20.
Stork and his co-workers met a formidable challenge for the time through a rather elegant
series of transformations. However, the 11 total steps would later be proved exhaustive and not
feasible on preparative scales. In 1976 Dauben’s group recognized that the dienophilicity
(tendency of a alkene to undergo 4+2 cycloaddition) of dimethyl-maleic anhydride (7) was
insufficient21. Diels-Alder reactions proceed most rapidly by combination of electron rich dienes
and electron deficient alkenes (dienophiles), which provides the necessary energies of the
dienophile LUMO and diene HOMO. The presence of electron donating methyl groups of
dimethyl-maleic anhydride (7) significantly decreases dienophilicity and imparts unfavorable
sterics in a Diels-Alder transition state. Furan (8) was also considered a poor diene due to its
6

aromaticity, having less tendency to transfer electrons to electron deficient systems compared to
cyclopentadiene22. The propensity of this system to undergo retro-Diels-Alder when heated was
also recognized22. Dauben et al surpassed the limitations by employing a cyclic thioether
derivative of maleic anhydride 9 in the Diels-Alder reaction with furan (8) to circumvent
unfavorable sterics from the dimethyl groups of 7. Elevated pressure was employed to avoid the
need for high temperatures, which avoided a retro-Diels-Alder process, pyrolysis of the thioether
bridge and to overcome the steric hindrance imparted by the cyclic thioether21 (Scheme 3).

Scheme 3- Dauben et al optimized preparative scale synthesis of cantharidin (1)21.
Under the optimized conditions (7 kbar, RT, 16eq furan (8)), full conversion of thioether
anhydride 9 and furan (8) to Diels-Alder adducts 10 and 11 was observed21. The resulting
isomers were then reduced and desulfurized with catalytic Raney Ni, giving cantharidin (1) and
its endo isomer 1221. Selective recrystallization from ethyl acetate yielded pure cantharidin (1) on
a 10-15g scale in 51% yield21.

7

Diels-Alder reactions are deceptively simple transformations with immense utility.
However, variables and nuances that either rationalize reaction products or lack thereof were
understood long after its application in synthesis. FMO theory has since provided explanations
that provide controllable and predictable products. Diels-Alder reactions generally favor endosubstituted products due to stabilization of an endo-approach transition state by secondary orbital
overlap (Figure 2)19.

Figure 2- Stabilization of the endo approach transition state through secondary orbital reactions.

Woodward and Hoffman also illustrated molecular orbital (MO) considerations that
accurately predict stereochemical outcomes of electrocyclic reactions23. Enantioselective DielsAlder reactions are possible using chiral auxiliaries and chiral lewis acid activators and
organocatalysis, such as camphor sulfonyl hydrazines24,25. A great deal of regioselectivity is
possible based on position of electron donating (EDG) electron withdrawing (EWG) groups on
dienes and dienophiles and is rationalized by MO and FMO theory26. Diastereoselectivity can be
controlled when considering temperature, solvent systems, pressure and steric bulk on dienes or
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dienophiles as well as the presence of Lewis acids26. Because a considerable amount of control is
possible through Diels-Alder transformations, its utility in synthetic chemistry is far reaching.
1.4- Previous Synthesis Biological Evaluation of Cantharidin Based Molecules
Closely related analogues of cantharidin have also seen considerable attention. The mono
methyl analogues, (+)-palasonin (3) and (-)-palasonin (2) were synthesized enantioselectively by
Dauben and co-workers in 1996 (Scheme 4)27.

Scheme 4- Synthesis and resolution of (+)/(-)-palasonin from Dauben et al27.
Their work with this system revealed an optimized Diels-Alder transformation of furan
(8) and methyl-maleic anhydride 13 was dependent on the molar equivalent of furan, pressure
applied and reaction time27. Due to the propensity of Diels-Alder products to undergo retroDiels-Alder process (cycloaddition products revert to starting diene and dienophile), an excess of
furan favors Diels-Alder products, however greater than 1.1eq of furan (8) in this system used
yields diaddition products and later found 1.05eq of furan minimizes the formation of diaddition
9

products27. Using 1.05 eq. of furan, investigation of reaction time and pressure employed showed
optimal yields were obtained after 138h under 8 kbar of pressure, giving (+/-)-palasonin in 99%
yield and no detectable amounts of endo isomer products27. The racemic mixture was resolved
by reaction with 2eq. of (S)-(-)-α-methylbenzylamine to form diastereomeric amides, that were
separated and saponified to diacids and subsequent reaction with thionyl chloride yielded (-) and
(+) palasonin (3) and (2), respectively27.
Notably, a study from Lee and Herndon on the stereochemistry of the Diels-Alder
reaction of furan (8) and maleic anhydride (15), it was described that the thermodynamic exo
product is favored (Scheme 5)28.

Scheme 5- Facile synthesis of norcantharidin 4 from Lee and Herndon28 and Hill et al29.
Although the endo isomer forms at a faster rate it spontaneously undergoes a retro-DielsAlder/Diels-Alder process and the resulting equilibrium results in a majority of exo isomer
products12,28. Synthesis of the non-methyl containing analogue, norcantharidin (4), is
considerably easier due to minimized steric hindrance and electron donating effects of dimethyl
and methyl maleic anhydrides 7 and 13. Facile synthesis is achieved with a room temp,
atmospheric pressure Diels-Alder reaction of maleic anhydride and furan followed by
hydrogenation with Pd/C and 4atm of H2 (g)29.
Modifications to the oxabicyclo [2.2.1] heptane core has also received attention in recent
years. A thio-bicyclo analogue of cantharidin has been synthesized by McCluskey et al through
10

the reaction of anhydride 15 and thiophene (16) under elevated pressure (Scheme 6)30. The
resulting analogue displayed inhibition of a protein phosphatase30.

Scheme 6- Synthesis of thio-bicyclo analogue 17 from McCluskey et al30.
Fluorinated maleic anhydrides 18-20 were synthesized by Essers et al in 2001 and used in
Diels-Alder reactions with furan (8) to generate fluorinated norcantharidins 21-23 (Scheme 7)31.

Scheme 7- Synthesis of fluoronorcantharidins 21-23 by Essers et al31 (top). Difluoro adduct 21
rapidly undergoes saponification to diacid 24 when exposed to air moisture (bottom)31.
Monofluorinated derivatives 22 and 23 were reported as stable. However, the difluoro DielsAlder adduct 21 formed by the reaction of 18 and 8 was found to be unstable and rapidly
converted to diacid 24 upon exposure to air moisture. The isolated diacid was reduced to stable
endothall 25 and isolated.
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Modifications to the 5 position of the oxabicyclo [2.2.1] core of norcantharidin 1 were
investigated with reactions of 3-substituted furans by Tatlock et al in 1997 (Scheme 8) on the
basis of computational docking of cantharidin to human protein phosphatase 1 (PP1)32.

Scheme 8- Synthesis of norcantharidin derivatives from furanyl esters 26a-j by Tatlock et al
Furanyl esters 26a-j underwent Diels-Alder addition with maleic anhydride (15) under ambient
conditions and were reduced to the corresponding norcantharidin derivatives 27a-j in high
yield32. All exhibited PP1 and PP2B inhibitory activity32.
Notably, Cott et al showed in 2005 that reactions of furfuryl compounds 28a-c and
maleic anhydride (15) proceeds roughly 10 times faster in supercritical CO2 than in diethyl ether
(Scheme 9)33.
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Scheme 9- Synthesis of norcantharidin analogue precursors 29a-c in supercritical CO2.
The accelerated rate of this reaction provided a solution to low yielding results in the
reaction of similarly substituted furans with maleic anhydride (15) encountered by Hart et al34.
The conditions also provide access to endo-norcantharidin type structures that are difficult to
isolate as their retro-Diels-Alder reaction process occurs rapidly and re-conversion to the exo
isomer is favored. More recent attention turned to modifying the anhydride ring of
norcantharidin (4) from Tarleton et al in 2012 (Scheme 10)35.
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Scheme 10- Generating alkoxy norcantharidin analogues 34 a-c and 35 a-k from
hydroxylactones 32 and 33 (top). Installation of various terminal phosphate groups to alkyloxy
lactone 36 (bottom) from Tarleton et al35.
Precursor 30 was synthesized from anhydride 15 and furan (8) (see Scheme 5)35.
Simultaneous reduction of the alkene and one carbonyl of 30 was achieved with 4 bar H2 and
Pd/C in ethanol of generating hydroxylactones 32 and 33 which were separated by selective
recrystallization35. Hydroxylactones 32 and 33 were then used to generate a library of alkoxy
derivatives with unsaturated, straight, branched and cyclic chains by exposing the hydroxy
lactone to the corresponding alcohol in the presence of catalytic para-toluenesulfonic acid (pTsOH) under microwave (µW) irradiation35. Notably, these reactions were successful with small
and large alkyl chains and with alkyl substituents bearing synthetically useful alkene and alkyne
moieties. Alkenes 34a, 34b, 35a and 35b were successfully epoxidized with mCPBA to the
corresponding racemic epoxides35. In the same study, various terminal phosphate groups were
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installed to alkyloxy norcantharidin lactone 36 by treatment with the corresponding organo
phosphate in the presence of dibutyltin oxide (Bu2SnO)35. The generated library of compounds
was tested for PP1/PP2a inhibition and generated several molecules with significant activity35.
1.5- Previous Syntheses and Biological Evaluation of Cantharimide and Based Molecules
The closely related imide counterpart, known as norcantharimide (5), has received most
of the recent attention in developing new cantharidin analogues. The Diels-Alder reaction of
furans and maleimides to prepare cantharimides are suboptimal due to lack of selectivity to form
the desired bioactive exo isomers12 (Scheme 11).

Scheme 11- General Diels-Alder reaction for norcantharimide (6) from furan (8) and maleimide
(37).
Combining maleimide (37) and furan (8) gives significant amounts of both exo 6 and endo 38
Diels-Alder products29. The desired bioactive exo isomers then need to be isolated by
chromatography. Cantharimide/norcantharimides are of interest as they still possess biological
activity but exhibit less acute toxicity to mammalian enzymes29,36. The less toxic imides have
been most commonly prepared in condensation of cantharidins with primary amines12. In 2001
McCluskey et al generated 16 norcantharimide derivates 39 a-p by treating commercially
available norcantharidin (4) with various amino acids (AAs) in toluene and triethylamine at
200°C (sealed tube) with modest yields (Scheme 12)29.
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Scheme 12- Synthesis of N-amino acid cantharimides by McCluskey et al.
In evaluating the inhibition of PP1 and PP2 of compounds 39a-p, tyrosine (39i and 39j),
tryptophan (39m and 39n) and histidine (39k and 39l) residues showed the greatest inhibition,
suggesting the greatest activity is achieved by instillation of bulky aromatic side chains36.
Detectable variation in inhibition was noticed upon the addition of D or L AAs, where the natural
L-enantiomers generally showed slightly higher inhibition36.
In 2007 Hill et al synthesized various N-alkylamines with short and long alkyl chains,
cycloalkyl, unsaturated, hydroxyl and carboxylic acid substituents29 (Scheme 13). Starting
material norcantharidin (4) was prepared on high scale readily by the exo-selective cycloaddition
of furan (8) and anhydride 15 (rt, 48h in diethylether) that was subsequently reduced under H2 (g)
(4 atm) in the presence of Pd/C29.

Scheme 13- Addition of various amines to norcantharidin (4) to generate norcantharimide
derivatives 40 a-m by Hill et al29.
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Compounds 40 a-m were then tested for activity against colon, breast, ovarian, lung, skin,
prostate, neuronal and brain cancer cell lines29. The most potent inhibitors were those bearing
8C-14C alkyl chains (40g-j) across all lines29. N-vinyl derivative 40l showed the most potent
inhibition across several lines29. Both unsaturated chain derivatives 40l and 40m were
susceptible to epoxidation (mCPBA) and dihydroxylation (OsO4/NMO)29, providing access to
even more derivatives by this method.
Two bis-cantharimides were prepared by treating norcantharidin (4) with terminal
diamines, 1,3-diaminopropane and 1,12-diaminododecane (Scheme 14).

Scheme 14- Generation of bis-cantharimides 41 a and b by Hill et al29.
The two bis-norcantharimides 41a and 41b showed greater cytotoxicity than their monomer
counterparts29. Notably, the dodecane linked bis-cantharimide 41b showed greater cytotoxicity
than norcantharidin (4)29.
The facile addition of various amines demonstrated by the Hill and McCluskey groups
allowed for preparation N-heteroatomic substituted cantharimides by Kok et al (Scheme 15)37.
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Scheme 15- Synthesis of thiazole cantharimides 42 and 43 a-d from Kok et al37.
Addition of aminothiazoles was achieved by the established method29. The synthesized
aminothiazole derivatives 42 and 43a-d were all shown to exhibit prominent anti-tumor
activity37. Further, installation of aminothiazoles in 43a-d were shown to increase toxicity to
malignant cells while showing less toxicity to healthy cells when compared to cantharidin (1)37.
Further, 43 a-d were found to induce apoptosis in SK-Hep-1 hepatoma cells37. Disulfide linked
N-aminothiadiazole cantharimide dimers have also been prepared the Kok group38(Scheme 16).

Scheme 16- Synthesis of disulfide linked N-thiadiazole cantharimide dimer 44 by Kok et al38.
The dehydrative condensation of cantharidin and norcantharidins with primary amines
was insufficient for anilines until an improvement from Deng et al employed catalytic
manganese (II) acetate (Mn(OAc)2) synthesizing various N-aryl norcantharimides (Scheme 17)39.
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Scheme 17- Synthesis of N-aryl norcantharimides 46 from dehydro-norcantharidin 45.
A plethora of modifications to the [2.2.1] oxabicyclio heptane core of cantharimide and
norcantharimide have been achieved. Further analogues were developed by Thaqi et al where the
oxabicyclo heptane core is replaced by a 5,6 heteroatomic bridge and then further derivatized by
the addition of AAs and AA esters to the anhydride ring (Scheme 18)40.

Scheme 18- Synthesis of heteroatomic fused imide cantharimide analogues 51-54 a-p from
Thaqi et al
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The starting succinic anhydrides 47-50 were transformed to corresponding imides 51-54
a-p with various AAs and heterocycle or alkyhydroxy substituted amines promoted by
microwave (µW) irradiation40. In bioactivity assays the starting anhydrides 47-50 were not active
against cell lines that cantharidin (1) and norcantharidin (4) significantly inhibited40. This
suggests the importance of the ethyl bride and ethereal oxygen of the oxabicyclic core of
cantharidin (1) and norcantharidin (4) for bioactivity40. The majority of analogues did not show
increased cytotoxicity compared to cantharidin (1) and norcantharidin (4)40. However, it was
noted that N-octyl derivative 51p showed greater cytotoxicity than 1 and 440. This finding
suggests the benefit of longer N-alkyl chains, in agreement with the observed potency of N-C814 chained cantharimide derivatives 40 g-k from Hill’s group (Scheme 13)29. Analogue 48p was
also found to be equipotent to norcantharidin (4) across the same cell lines40.
Further derivatives from Rojas and Kouznetsov were generated through modifications of
a carbonyl functionality on norcantharidin (4) (Scheme 19)41.

Scheme 19- Generation of lactam norcantharimide derivatives 57 from Rojas and Kouznetsov41.
Treatment of norcantharidin 4 with ylide 55 generated olefinic lactone 56 which was
susceptible to condensation with 20 different amines to generate library 57. Notably, under these
careful conditions, the bicyclic core essential for bioactivity40 remains intact.
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In 2010 Goksu et al exploited the double bond of 5,6-dehydro-norcantharimide 58 and
methylene bridged analogue 59 to selectively generate exo-arylated analogues 60 a-f and 61 a-c
through a Heck arylation process (Scheme 20)42.

Scheme 20- Arylation of the [2.2.1] bicyclo heptane norcantharimide core via reductive Heck
arylation from Goksu et al42
The procedure is relatively robust as multiple aryl substituents were successfully
installed, including the sterically encumbered biphenyl residue 60c and thiophene 61c.
Further modification at the 5,6-position of dehydrocantharimides came from Deng et al
through 1,3-dipolar cycloaddition of dehydronorcantharimides and nitrile oximes (Scheme 21)43.

Scheme 21- 1,3-dipolar cycloaddition of norcantharimides 62 to generate isooxazolines 64.
Deng’s group generated a library of isooxazolines 64 from 20 different aryl
norcantharimides 62 by the 1,3-dipolar cycloaddition with nitrile oxime 63 in the presence of N-
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chloro tosylamide (Chloramine T)43. This procedure also served to install the common
trimethoxyphenyl pharmacophore in a robust fashion.
Furans bearing substituents in the two position had previously gave poor yields in DielsAlder reactions with maleic anhydride (15), which was subsided by reaction in supercritical CO2
by Cott et al33. Similarly, the reaction of furfuryl amines would be expected to proceed
sluggishly in Diels-Alder reactions. Galvis et al discovered that employing boric acid can
accelerate Diels-Alder reactions of furfuryl amines and maleimides (Scheme 22). Diene 65
successfully underwent Diels-Alder addition with N-substituted maleimides 37, 66 and 67 by
employing catalytic boric acid in PEG-40044 (Scheme 22).

Scheme 22- exo-Selective synthesis of dihydronorcantharimides 68 a-c from furfuryl amide 65
and maleimides 37, 66 and 67 using catalytic boric acid from Galvis et al44.
We presume the coordination of boron to oxygens of carbonyls of the imide functionality favors
the formation of the exo-DA product by blocking the endo approach of furfuryl diene 6544. This
coordination likely also accelerates the rate of Diels-Alder adducts 68 a-c indicated by the short
reaction time44.

22

1.6- Summary of Biological Activity of Cantharidin and Cantharimide Based Molecules
Since its discovery, cantharidin and its analogues have been the focus of synthetic
chemists in hopes of developing new analogues with selective anti-proliferative effects while
minimizing the toxicity of the parent NP molecules. Several trends are apparent when comparing
analogue structure to biological activity. As discussed, cantharidin acts to cause cell death by
protein phosphatase inhibitory activity36. In a recent review from Galvis et al, the most potent
PP1/PP2 inhibitors were summarized (Table 1)12.
Table 1- Most potent PP1/PP2 inhibitors as summarized by Galvis et al12.
Compound
PP1 Inhibition (IC50 µM)
PP2 Inhibition (IC50 µM)
1
3.6 ± 0.42
0.36 ± 0.08
6
5.31 ± 0.36
2.9 ± 1.04
39l
3.22 ± 0.7
0.81 ± 0.1
39k
2.82 ± 0.5
1.35 ± 0.3
69
13 ± 5
7.0 ± 3.0
70
18 ± 8
3.2 ± 0.4
71
12.5
426
72
5.9 ± 2.2
0.79 ± 0.1
*Compounds 69-72 not discussed. Primary Ref: 1, 6, 39l, 39k, 7136, 69-7234

Cantharimide derivatives bearing an N-substituted aromatic species 39l, 39k and 69 were
shown to be greater PP inhibitors than aliphatic derivatives12. In imide ring opened derivatives,
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strongly polarized carboxylate salt 70 and N-heterocycle amide 72 analogues proved to be potent
inhibitors along with thio-bicyclo cantharidin derivative 7112.
Cantharidin based molecules cytotoxicity to human cancer cell lines has also been
assessed extensively (Table 2)12,35,29,40. Across some human cancer cell lines, the alkyloxy
lactone cantharidin analogues from Tarleton et al35 showed potent cytotoxicity. Cytotoxicity
against more strains was observed when terminal phosphate groups were installed to the
alkyloxy moiety of the alkyloxy lactone in cantharidin analogues 37 a-d35. Unsurprisingly, the
same amide carboxylate salt 70 to show potent PP inhibitory activity from Hart et al34 also
showed potent cytotoxicity against several cancer cell lines34. Additionally, the dodecane linked
bis-norcantharidin analogue 41b from Hill et al29 showed potent cytotoxicity across several lines.
Similar results were observed with long chain N-alkyl, N-propyl(1-hydroxy-2-methoxy)
norcantharimide analogues from McCluskey et al36. Finally, 1,3-heteroatomic bridged
norcantharimide species showed potent cytotoxicity.
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Table 2- Most potent tumor cell growth inhibitors as summarized by Galvis et al12.
Tumor Cell Line
Cpd
1

A2780
10 ± 4

34b

H460
4.3 ±
0.9
50 ±
4
41 ±
9.2
>100

L1210
15 ± 2

40 ±
10
57 ± 5

G401
3.5 ±
0.3
35 ±
2.3
25 ±
1.5
N.D.

4

39 ± 5

70

34c

20 ± 1

N.D.

>100

N.D.

34d

>100

N.D.

>100

N.D.

73

22 ± 2

N.D.

>100

N.D.

74

N.D.

40j

35 ± 4

N.D.

75

<10

N.D.

13 ±
0.3
53 ±
4
66 ±
7
<10

N.D.

40i

7.7 ±
0.3
40 ± 4

41b

19 ± 1

N.D.

N.D.

51p

30 ± 0

N.D.

52p

58 ± 0

N.D.

31 ±
7
71 ±
1
81 ±
8

N.D.

13 ±
0.3
48 ±
1.5
N.D.

N.D.
N.D.
N.D.

N.D.
N.D

HT29
8.4 ±
0.7
33 ±
7
N.D.

SW480
N.D.

MCF-7
N.D.

A431
N.D.

DU145
N.D.

BE2-C
N.D.

SJ-G2
N.D.

41 ± 4

34 ± 3
N.D.

90 ±
10
N.D.

36 ± 0

N.D.

72 ±
3
N.D.

23 ±
5
N.D.

42 ±
5
32 ±
3
19 ±
1
17 ±
1
11 ±
0.3
25 ±
4
19 ±
0
12 ±
4
8.3 ±
0.7
21 ±
1
59 ±
1

93 ± 8

>100

>100

84 ± 5

39 ± 4

77 ±
10
27 ± 6

>100

38 ± 2

94 ± 1

>100

68 ±
5
>100

>100

44 ± 5

9±7

20 ± 1

84 ± 3

9 ± 0.2

10 ± 03
55 ± 2

12 ±
0.9
52 ± 8

13 ±
0.9
66 ± 4

9.3 ±
0.1
40 ± 6

56 ± 4

43 ± 7

73 ± 2

50 ± 4

<10

33 ± 3

87 ±
12
12 ±
0.3
35 ±
4
47 ±
3
<10

<10

<10

24 ± 4

18 ± 0

60 ± 6

17 ± 4

29 ± 2

22 ± 4

33 ± 2

59 ± 4

68 ± 2

41 ± 1

18 ±
4
36 ±
1
61 ±
2

70 ± 2

68 ± 2

N.D.

55 ±
3
37 ±
6
21 ±
3
43 ±
3.4
14 ±
0.3
58 ±
2
49 ±
5
<10
43 ±
10
28 ±
0
65 ±
5

Cpd=Compound – N.D. = Not Determined
Values expressed as lowest GI50 µM
Primary Ref: 1, 4, 7036, 34 b-d, 73, 7435, 40i-j, 75, 41b29, 51p and 52p40. See Fig 3 for structures.
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Figure 3- Structures of most potent tumor cell inhibitors as summarized by Galvis et al12.

1.7- BMS-641988
A notable analogue sharing its core structure with norcantharimide (6) is BMS-641988
(75), developed from a series of [2.2.1]-oxabicyclo imide-based androgen receptor (AR)
antagonists by researchers at Bristol-Meyers-Squibb45.

Figure 4- Structures of BMS-641988 and FDA approved hydroxyflutamide and bicalutamide.
BMS-641988 is a novel rational design based AR antagonist currently in clinical
development45. Androgen receptor antagonists in combination with anti-androgens (chemical
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castration) and surgical castration is the current standard of treatment for carcinoma of the
prostate (CaP)46. About 50% of those that do not respond to initial treatment go on to develop
castration resistant prostate cancer (CRPC) characterized by resistance to current androgen
antagonists47. The need for novel androgen receptor antagonists arises from this resistance to
current androgen receptor antagonists, including FDA approved hydroxyflutamide (76) and
bicalutamide (77)47. BMS-641988 (75) has shown greater androgen receptor binding
(Ki=1.7nM), antagonist activity and anti-tumor activity (MDA-MB-453 IC50=16nM) compared
to bicalutamide in in vivo assays (Figure 4)45. The structure of BMS-641988 (75) features a 1,4dimethyl-N-aryl-5-endo-sulfonamide derivation from norcantharimide (6).
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Scheme 23- Synthesis of BMS-641988 7545.
The synthesis of BMS-641988 (75)45 (Scheme 23) began by generating the N-(3trifluromethyl-4-cyano)phenyl maleimide 78 by dehydrative condensation of anhydride 15 with
the corresponding aniline 77. The diastereoselective generation of the exo cycloadduct is
achieved by a Diels-Alder reaction with sterically encumbered furan 82 at 120°C, a remarkable
diastereoselective Diels-Alder without the use of a Lewis acid catalyst. Reduction of the 5,6alkene with H2 (g) and Pd/C generates the endo ester 79 and following chiral HPLC separation
gives the active enantiomer 80 from the racemic exo-Diels-Alder adduct 79. Acid catalyzed
hydrolysis from 80 gives the corresponding acid and a subsequent Curtius rearrangement in the
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presence of 2-(trimethylsilyl)ethanol generates the corresponding Teoc-carbamate. TFA
promoted cleavage of the resulting carbamate generates the endo-amine 81. Finally, the endoamine is coupled to EtSO2Cl under basic conditions to yield BMS-641988 (75).
1.8- Proposed Work
Due to the recent development of BMS-641988 (75), the plethora of modifications
possible to cantharidin and cantharimide type molecules and the extensive bioactivity of
cantharidin based molecules, we plan to synthesize a series of cantharidin/cantharimide based
NP analogues for the discovery of new molecules with anti-proliferative properties. We employ a
forward thinking synthetic strategy beginning with reactions of N-alkylmaleimides, maleic
anhydride (15) and 2,5-dimethylfuran (82) due to structural similarity of corresponding DielsAlder products and the BMS lead structure (Schemes 24 and 25).

Scheme 24- Proposed route to dimethylnorcantharidin core structure 83 from 2,5-dimethyl furan
and maleic anhydride 15.

Scheme 25- Proposed route to dimethylnorcantharimide core structures from 2,5-dimethylfuran
and N-alkylmaleimides.

29

A successful Diels-Alder reaction of furan 82 and anhydride 15 would generate a 1,4dimethylnorcantharidin structure and would likely proceed without the need for high pressures.
This represents a key intermediate in this synthetic endeavor due to the overwhelming
modification possibilities namely, through the reactivity of the 5,6-double bond and anhydride
ring as shown in the development of numerous cantharidin analogues as described. A DielsAlder reaction of furan 82 with N-alkylmaleimides would produce a dimethyl-norcantharimide
structure that may be modified at the alkene and by the synthesis of various N-alkylmaleimides.
Once sufficient derivatives have been generated, selected compounds will be tested by a
collaborator for biological activity and modified as necessary in order to discover new molecules
with anti-proliferative properties.
2- Results and Discussion
2.1- Diels-Alder Reactions of anhydride 15 and furan 82
The first Diels-Alder system investigated the reaction of furan 82 and anhydride 15 to
generate the 1,4-dimethyl-5,6-dehydronorcantharidin core structure 83 (Scheme 26).

Scheme 26- Synthesis of Diels-Alder adduct 83
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Figure 5- Comparison of purified Diels-Alder adduct 83 at times t=0hr and t=16hr by 1HNMR.
It was first found that the Diels-Alder reaction of maleic anhydride 15 and furan 82
proceeds rapidly at room temperature (RT) in ethyl acetate (EtOAc) (Scheme 26). Fifty percent
of starting anhydride 15 was converted to Diels-Alder adduct 83. The neat reaction also proceeds
at RT in similar fashion. Attempts to purify Diels-Alder adduct 83 by chromatography failed due
to instability on silica. Recrystallization of the crude product from diethyl ether (Et2O) yielded a
mixture of 80% Diels-Alder adduct 83 to 20% starting anhydride 15 by 1HNMR integration
(Figure 5). The corresponding alkene peak of 83 is observed at 6.36ppm at time t=0hr. At time
t=16hr, the alkene peak of 83 is diminished, the starting furan 82 is observed (2.25 and 5.83ppm)
and the ratio of anhydride 15 (7.04ppm) to the solvent residual peak (7.26ppm) is increased,
indicating the propensity of Diels-Alder adduct 83 to undergo a retro-Diels-Alder reaction at RT.
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Scheme 27- Reduction of crude Diels-Alder adduct 83 to reduced adduct 84 and anhydride 85.
It was believed instability to silica observed during purification of Diels-Alder adduct 83
was due to the tendency of crude adduct 83 to undergo a retro-Diels-Alder reaction and
hydrogenation of Diels-Alder adduct 83 would be necessary before purification by
chromatography (Scheme 27). Purification of reduced adduct 84 by chromatography failed,
suggesting the anhydride moiety is responsible for the instability on silica, which was confirmed
by 2D TLC experiments.

Scheme 28- One pot DA/reduction reaction to isolate reduced adduct 84
A one pot Diels-Alder/reduction reaction was conducted anticipating the Diels-Alder
product 83 would be immediately reduced to adduct 84, thereby favoring the Diels-Alder product
in the Diels-Alder/retro-Diels-Alder equilibrium (Scheme 28). However, we observed that
anhydride 15 is also reduced to anhydride 85 in this process, therefore the equilibrium of the
Diels-Alder reaction could not be manipulated to solely produce Diels-Alder adduct 84.
However, we did note only exo Diels-Alder products are obtained in the reaction of anhydride 15
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and furan 8248. This prompted investigation of exploiting the exo selectivity of this reaction to
generate 1,4-dimethylnorcantharimides (Scheme 29)

Scheme 29- Synthesis of reduced N-benzyl Diels-Alder adduct 100 from anhydride 15.
Addition of nucleophiles to the reduced core structure 84 would serve as a route to
selectively generate exo-1,4-dimethyl-norcanthraimides. Products 83 and 84 were used in
subsequent steps without purification and the reduced exo-N-benzyl Diels-Alder adduct 100 was
synthesized successfully from anhydride 15 (16% overall)29. This success opened the possibility
of adding varying amine nucleophiles into the anhydride ring. This route proved advantageous
not only from complete exo selectivity, but also that molecular diversity is added in the form of
an amino nucleophile at the final stage of the route. Complete exo selectivity in the formation of
83 was initially surprising to our group but later rationalized from theoretical and experimental
observations by Rulisek et al (Figure 6)49.
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Figure 6- Theoretical calculations of transition state energies (kJ/mol) of the Diels-Alder
reaction between furan (8) and maleic anhydride (15) from Rulisek et al49.
Rulisek and co-workers report theoretical data that suggests a Diels-Alder reaction of anhydride
15 and furan (8) proceeds uniquely to form only exo isomer 4 (Figure 6)49. Due to nearly
identical transition state energies between endo and exo forming reactions, exo product 4 is
strongly favored thermodynamically (-11.5kJ/mol) and even slightly kinetically (-0.3kJ/mol).
Their theoretical calculations were supported by experimental evidence through analysis of the
reaction of 15 and 8 by 1HNMR49. We expect our system employing 2,5-dimethylfuran (82) in
the reaction with anhydride 15 proceeds in a similar fashion, mainly due to no detectable
formation of the endo counterpart in 1HNMR experiments and the propensity of the
thermodynamic exo product 83 to undergo a retro-Diels-Alder reaction at room temperature
(Figure 5). Further modifications of the core Diels-Alder structure 83 were also investigated.
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2.2- Post Diels-Alder Modifications to Diels-Alder adduct 83
Due to the plethora of modification possibilities to Diels-Alder product 83 at the 5,6alkene and labile anhydride ring, modifications to the core structure were of interest.

Scheme 30- Attempted iodolactonization of Diels-Alder adduct 83.
Iodolactonization of Diels-Alder adduct 83 was investigated in effort to generate the
synthetically useful halolactone 96 for subsequent modification (Scheme 30). Iodolactonization
from 83 to 96 failed under precedented conditions50. Presumably, the bond angle in the exo
conformation of the fused anhydride would be too strained in the attack of the intermediary
iodonium ion. This is likely considering reports where diastereomers of Diels-Alder reactions
can be resolved by iodolactonization where endo isomers are isolated as the halolactones50.
Therefore, generating general epoxide 97 was not feasible. For endo Diels-Alder adducts of
maleimides, an iodolactamization is theoretically possible. Bromination of the 5,6-alkene was of
interest as a pseudo-protecting group of the alkene (Scheme 31).

Scheme 31- Synthesis of dibromo Diels-Alder adduct 98 as an alkene protecting group.
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The tendency of the Diels-Alder adduct 83 to undergo retro-inversion was a concern for
future modifications to the anhydride ring. Bromination proceeded as expected under the
prescribed conditions51. Debromination with KI was not achieved, and the reason is proposed to
be that the Br atoms cannot achieve the anti-periplanar conformation required. Debromination
with activated Zn in the presence of AcOH remains a possibility52. Generating synthetically
useful epoxides from the 5,6-alkene of 83 was also investigated.

Scheme 32- Attempted epoxidation of Diels-Alder adduct 83.
Epoxidation of Diels-Alder adduct 83 with mCPBA for epoxide 99 was unsuccessful
(Scheme 32). Alpha protons of the fused bicycle/anhydride ring were not present in 1HNMR of
the crude product indicating the anhydride moiety does not remain intact in the presence of
mCPBA. Attempted epoxidation with DMDO generated in situ from acetone and oxone resulted
in no discernable 1HNMR signals, alluding to reactivity of the anhydride moiety to peroxides.
With valuable information gathered in the Diels-Alder reaction to form 1,4-dimethylnorcantharidin analogues 83/84 and in the modifications of these core structures, we investigated
Diels-Alder reactions of furan 82 from varying N-alkylmaleimides.
2.3- Diels-Alder reactions of N-alkylmaleimides
The profiling of Diels-Alder reaction systems from N-alkylmaleimides began with the
reaction of N-methylmaleimide (86) and furan 82 (Scheme 33).
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Scheme 33- Pathway to resolve and characterize exo/endo products from Diels-Alder reactions
of furan 82 and maleimide 86.
Maleimide 86 was treated with furan 82 in ethyl acetate (EtOAc) at RT then the endo/exo
isomers were separated by chromatography to exo 58 and endo 87 Diels-Alder adducts. Both
adducts were then separately reduced with H2 in the presence of Pd/C (Scheme 33) and the
identity of endo/exo isomers was elucidated through NOESY experiments (Figure 7).
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Figure 7- NOESY experiments to determine identity of endo 87 and exo 58 isomers from the
Diels-Alder reaction of maleimide 86 and furan 82.
The identity of exo adduct 58 was assigned upon observing that α-protons of the fused
maleimide moiety in reduced counterpart 88 exhibit NOE coupling to axial protons across the
bicycle (Figure 7, right). The identity of endo adduct 87 was confirmed upon observing αprotons of the fused maleimide structure in reduced counterpart 89 exhibit NOE coupling to
methyl protons of the bicycle (Figure 7, left). The pseudo-equatorial α-protons of endo isomers
89 and 87 were more deshielded due to a C-C single bond anisotropic effect common in
conformationally fixed rings53. The observable trend was applied to subsequent reaction systems
to identify endo/exo isomer ratios.
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Table 3- Resulting endo/exo isomer ratios from Diels-Alder reactions with furan 82 and Nalkylmaleimides with varying time, temperature and solvent (ratios by 1HNMR integration).

Entry
1
2
3
4
5
6
7
8

Time
24hrs
24hrs
24hrs
24hrs
24hrs
24hrs
96hrs
3hrs

R=
Me
Me
Me
Me
Ph
Bn
Me
Me

9

3hrs

Ph

10

96hrs

Ph

Solvent
EtOAc
Et2O
DCM
EtOAc (reflux)
EtOAc
EtOAc
EtOAc (reflux)
1,4-dioxane
(30 mol %
H3BO3)
1,4-dioxane
(30 mol %
H3BO3)
EtOAc (reflux)

Endo: Exo
66:34
67:33
74:26
56:44
74:26
77:23
22:78
23:77

9:91

25:75

N-alkylmaleimides were subjected to Diels-Alder reactions with furan 82 under varying
conditions and the resulting isomer ratios were determined by 1HNMR integration (Table 3). It
was evident that a more polar solvent aids in the formation of endo isomer 87 (entries 1-3).
Applying heat increased the formation of exo adduct 58 (entry 4).
N-phenyl 90 and N-benzyl 93 maleimides were synthesized to evaluate steric effects on
the corresponding Diels-Alder reaction systems. Surprisingly, Diels-Alder reactions with phenyl
and benzyl maleimides showed an increase in the formation of endo isomers 92 and 95 (entries
5-6). A possible explanation is increased stabilizing secondary orbital interactions from pi
orbitals of aromatic residues in the endo approach54. An increased reaction time in refluxing
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EtOAc assayed at t=1hr, 24hr, 48hr, 72hr and 96hr with maleimide 86 gave an appreciable
increase in the formation of exo adduct 58 (entry 7). An identical endo:exo ratio (22:78) was
observed at t=72hr and t=96hr, indicating the reaction of maleimide 86 and furan 92 is in
equilibrium after 72hr (entry 7). Selective generation of exo adduct 91 was achieved by treating
maleimide 90 with furan 82 in the presence of catalytic boric acid12 (H3BO3) with a prominently
shorter reaction time (entries 8-9).
We believed the endo:exo ratio between the reaction of maleimide 86 and furan 82 in
refluxing EtOAc for 96hrs represented a thermodynamic equilibrium, as the same endo:exo ratio
was obtained employing the boric acid catalyst (entries 7-8). It follows that the exo selectivity
achieved by using boric acid was a result of accelerating the rate of forward and reverse DielsAlder reactions, ultimately favoring the more stable thermodynamic product. However,
employing the same conditions that generate a thermodynamic equilibrium for maleimide 90 we
did not observe the same endo:exo ratios (entires 9-10). We postulate the exo selectivity of boric
acid likely stems from stabilization of exo transition states, accelerating the rate of formation of
exo products (entries 9-10), and not an overall acceleration of forward/reverse Diels-Alder
reactions to produce the thermodynamic exo product.
Upon profiling Diels-Alder reactions of maleimides 86, 90 and 93 with furan 82, we
investigated post Diels-Alder modifications of the corresponding cantharimide core structures.
Although exo selectivity had been achieved (entry 9), on preparative scales exo selective
conditions were not employed due to our desire to access additional molecular diversity through
the isolation and modification of both endo and exo isomers.
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2.4- Post Diels-Alder modifications to N-alkylmaleimide Diels-Alder adducts 91, 92 and 95
Table 4- Epoxidation of maleimide Diels-Alder adducts 91, 92 and 95.

Entry
1
2
3

Substrate
91 exo, R=Ph
92 endo R=Ph
95 endo R=Bn

Time
48hr
120hr
240hr

Product
101
102
103

Yield
86% (a)
83%
92%

(a) Yield=95% with 120hr reaction time.

For modifications to the cantharimide core structure, generating synthetically useful
epoxides were of interest. Epoxidation of Diels-Alder adducts 91, 92 and 95 proceeded normally
and were isolated by chromatography (Table 4). We predicted that endo substrates 92 and 95
would severely hinder the mCPBA approach from the endo face of the bicycle and exo
epoxidation was expected and observed (entries 2-3). We also expected a majority of exo
epoxides to be formed in the synthesis of 101 but were surprised to observe no detectable
formation of an endo epoxide. A possible explanation would be due to H-bonding coordination
of mCPBA to the oxo bridge of the bicycle and the obvious steric consideration the α-hydrogens
impart in starting adduct 91. Exo-epoxidation was determined by 2D 1HNMR experiments
(Figure 8).
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Figure 8- 2D NMR experiments identifying exo epoxidation in the synthesis of 101-103.
Epoxide 101 exhibited NOE coupling between α-protons of the fused maleimide
(3.04ppm) and axial protons across the bicycle (3.40ppm), similar to exo isomer 88. As a result,
the exo epoxide structure 101 was confirmed. Exo-epoxidation was confirmed in epoxide 102 as
the protons spanning the bicycle should exhibit strong W-effect coupling. Through bond Wcoupling was not observed in a COSY experiment of 102 confirming exo-epoxidation, an
assignment that was subsequently applied to epoxy adduct 103.
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Scheme 34- Attempted hydride reduction of epoxy Diels-Alder adduct 101 and proposed route
to acyl derivatives.
With epoxide groups installed, reduction of epoxy Diels-Alder adducts was of interest in
pursuit of installing acyl groups to the bicyclic core (Scheme 34). Treating Diels-Alder adduct
101 with NaBH4 under prescribed conditions showed epoxide 101 disappear from the reaction
mix after 5 days (TLC). GCMS indicated appreciable formation of alcohol 104 in agreement
with 1HNMR Data, albeit as a minor component of the crude mixture according to GCMS and
1

HNMR integration. More rapid reduction of 101 was observed using LiBH455, however only

trace amounts of alcohol 104 were detected in the crude reaction mixture by GCMS and
1

HNMR. Due to the minimal amounts of desired alcohol 104 generated from reduction with

NaBH4 and LiBH4, alcohol 104 was not isolated, as reduction by these means would not provide
a viable route to acyl analogues 105. Stronger reducing agents such as aluminum hydrides are
not a viable alternative as they are known to reduce imides56.
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2.5- Summary and Biological Activity of BMS-641899/Cantharidin analogues

Figure 9- Structures of BMS-641899/cantharidin analogues synthesized. Previously reported
compounds: 91-9257 58 and 8758, 83-8459,48. Novel Compounds: 100-103, 88-89, 94-95, 111.
At this point the group was comfortable with the chemistry and had prepared our first
generation of cantharidin analogues (Figure 9). Nine novel 1,4-dimethyl-norcantharimide
analogues were generated (100-103, 88-89, 94-95, 111) and structures confirmed by
conventional methods. Selected compounds were then tested for antibiotic activity in a
preliminary bioactivity assay, completed by Dr. Hudson’s group60 (Figure 10).
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Compound Numbering
Assay # Cmpd #
1
101
2
91
3
15
4
83
5
82
6
94
7
93
8
92

Figure 10- Preliminary antibiotic activity assay of synthesized analogues (courtesy of Dr. Andre
Hudson).
Epoxide 101 and maleimide adduct 91 did not show significant antibiotic activity.
Anhydride 83 and benzylimide 94 showed significant antibiotic activity, but the possibility for a
retro-Diels-Alder process was noted. The corresponding Diels-Alder substituents 15 and 93
showed significant antibiotic activity and Diels-Alder products 83 and 94 showed detectable
retro-Diels-Alder reactions in 1HNMR studies. No detectable retro-Diels-Alder reaction was
observed with N-phenyl adduct 91, nor any significant antibiotic activity. These factors suggest
that the antibiotic activity of DA adducts 83 and 94 may simply be due to an in vitro retro-DielsAlder process to antibiotic substituents 15 and 93. This concern also stems from reports that Nphenyl 90 and N-benzyl 93 maleimides exhibit antifungal activity61 and additional bioactivity62.
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To verify this assumption, the reduced N-phenyl and N-benzyl maleimides will be tested
(Courtesy of Dr. Andre Hudson). We then turned our attention to identifying our second
generation of synthetic targets.
2.6- Covalent Modification of the Androgen Receptor Hypothesis

Figure 11- In silico docking model of BMS-641899 in the ligand binding domain of human wild
type androgen receptor (used without permission from 45).
Based on in silico docking experiments (Figure 11) of BMS-641899 (75) binding to the
human wild type androgen receptor (AR) the authors report a key interaction for its high affinity
is H-bonding between the oxo bridge of 75 and an asparagine (N705) residue in the ligand
binding domain of the human wild type AR45. They report the sulfonamide of 75 forces a
reorientation of the phenylalanine (F876) residue, causing a significant reorientation of the
receptor explaining the high antagonist activity observed in vitro. We noted the presence of a
threonine (T877) residue adjacent to the reoriented F876 residue, which prompted the hypothesis
that the AR receptor can be covalently modified using N-substitued epoxy cantharidin analogues
(Figure 12).
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5,6-epoxy-1,4-dimethylnorcantharimides

Figure 12- (Top) Representation of BMS-641999 in the AR Ligand Binding Domain (Bottom)
Predicted covalent modification mechanism of the human AR.
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Figure 12 is a simplified comparison of BMS-641988 (75), former BMS-lead 106 and a
cantharidin epoxide analogue in the binding pocket of the AR. Former BMS lead 106 (Figure 11)
was reported to exhibit H-bonding interactions with the N705 residue through the exo hydroxyl
moiety along with the oxo bridge of the bicycle. Visualizing our series of 5,6-epoxy-1,4dimethyl-norcantharimides in the AR ligand binding domain, we postulate the N705 residue can
act as a Lewis acid to activate exo epoxide and the nucleophilic hydroxyl of T877 can attack the
activated epoxide, forming a covalent bond (Figure 12-bottom). This prompted a study to
develop a facile procedure to epoxy Diels-Alder adducts with varying N-substituents.
2.7- Studies towards a route to Diels-Alder adducts bearing epoxides
Table 5- Results from primary amine addition to crude epoxy anhydride material.

Amine
L-Glycine

R=

Yield
NR

L-Glutamic acid

NR

Cyclohexylamine

<5%

Amino acid substitutions of the epoxy norcantharimide structure were of initial interest
due to their availability and potential bioactivity. As reduction of the alkene moiety to prevent
retro-Diels-Alder of the anhydride adduct 83 is not possible, epoxidation attempted on the crude
adduct gave ambiguous NMR data (Table 5). A portion of the crude product from the
epoxidation was subjected to different amines using established con1ditions (see Scheme 29).
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Addition of the amine was still attempted as mCPBA likely oxidizes the labile anhydride ring to
the corresponding ester, which we expected to be displaced by an incoming amine. The crude
epoxy anhydride mixture was treated with primary amines under the described conditions (Table
5). Addition of the cyclohexylamine to the epoxy anhydride moiety generates a significant hit in
GCMS with agreeing NMR Data. Purification efforts showed the desired N-cyclohexyl adduct
109 co-elute with the N-cyclohexyl amide of meta-chlorobenzoic acid in poor yield (<5%).
Addition of amino acid residues did not produce detectable amounts of desired products 107 and
108.

Scheme 35- Alternative route to N-substituted epoxy Diels-Alder adducts (Courtesy of Jordan
Dejewski)63.
Due to difficulties encountered in the route described in Table 5, we decided that effort
was better placed in first generating appropriately substituted maleimides. Diels-Alder reactions
of the maleimides are more easily purified and readily undergo epoxidation with mCPBA (as in
Table 4). As an initial study in the first two steps of the sequence, N-glycinylmaleimide 110 was
synthesized from anhydride 15 and underwent a Diels-Alder reaction with furan 82 that was
subsequently reduced to the corresponding Diels-Alder adduct 111 (Scheme 35). Purification of
the reduced product 111 is in progress by a current Cody group member63.
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Scheme 36- Synthesis of N-Trp Diels-Alder adduct 113.
Considering N-amino acids with large, aromatic substituents gave the best PP1/PP2
inhibition among cantharidin analogues (Table 1)12, and non-site restricted computational studies
showed the epoxy-N-tryptophan-norcantharimide analogue to have high affinity to the AR63, Ltryptophan was of interest as a substituent. N-Trp maleimide 112 was synthesized according to
previous methods64 and treated with 2,5-dimethylfuran which generated Diels-Alder adduct 113
(83:17 endo:exo) (Scheme 36). Careful chromatographic purification did not resolve endo/exo
isomers Diels-Alder adduct 113 was characterized as an endo/exo mixture, from a small sample
of the crude product that was purified by chromatography. It was reasoned that if we subjected
adduct 113 to mCPBA treatment for the epoxide isomers, purification may be possible. (Scheme
37).

Scheme 37- Attempted epoxidation of N-Trp Diels-Alder adduct 113.
Initial epoxidation attempts of 113 with 1eq of mCPBA showed no disappearance of the
bicyclic vinyl protons noticed by 1HNMR analysis indicating epoxidation at the desired site had
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not occurred. To accelerate the rate of epoxide formation, adduct 113 was treated with an excess
of mCPBA (3eq). Crude mass spectrometry data suggested epoxidation had occurred at two sites.
Upon investigation we suspect the indole alkene is epoxidized as in 114 due to the susceptibility
of this functional group to oxidation65. The dioxide product 114 also appeared to form with one
equivalent of mCPBA employed. At this juncture we completed thorough in silico experiments
to identify targets that may be produced by facile methods that also give promising data of their
activity in the AR ligand binding domain63.
2.8.- Studies to Identify Next Generation of Synthetic Targets
Nineteen possible N-amino acid substituents of the endo and exo epoxy cantharimide core
were analyzed within the 2q7i active site of the human AR using PyRx screening software
(Figure 13)63.
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Figure 13- Results from PyRx ligand binding simulations of endo-epoxy-N-amino acid
cantharimides.
Lower Y-axis values (ΔG) represent a higher affinity to the active site. Each data point
represents 1 of 300 simulations for each N-AA corresponding to a single position in 3D space
within the active site. The blue bars represent median values. Due to the results of endo epoxy
analogues tested, N-His, N-Arg, N-Tyr, N-Lys substitutions of the epoxy cantharimide core are
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of interest as future synthetic targets. Under identical parameters, the exo epoxy N-amino acid
analogues were also simulated (Figure 14).

Figure 14- Results from PyRx ligand binding simulations of exo-N-amino acid epoxy
cantharimides.

Notably, amino acids bearing simple alkyl chain R-groups (Gly, Ala, Val, Leu) are
among derivatives showing the highest affinity to the 2q7i active site. As methods to synthesize
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N-glycinyl derivative 111 has been demonstrated63, these simple amino acid substitutions are of
primary interest as future synthetic targets for exo epoxy N-AA derivatives.
2.9- Conclusions and Future Work
We have characterized Diels-Alder reactions of 2,5-dimethylfuran with maleic anhydride
and various N-alkylmaleimides. A series of 1,4-dimethylnorcantharidin analogues were
synthesized, characterized and evaluated for biological activity. Theoretical studies were
performed, and a second generation of synthetic targets has been identified. Future work will
involve the synthesis of second generation targets and testing for biological activity. Based on
simulation of exo-epoxy-N-amino acid cantharimides, those bearing simple alkyl R-groups 124127 represent the primary targets (Figure 15). In order to evaluate our covalent modification
hypothesis, Dr. Michael Gleghorn, our collaborator in the School of Chemistry of Materials
Science will attempt capture the interaction of 5,6-epoxy-N-amino acid-1,4-dimethylnorcantharimides with the AR through conventional crystallographic methods.

Figure 15- Exo-epoxy-N-amino acid cantharimide future targets of primary interest.
In our closing synthetic efforts for Chapter 1 of this thesis, novel endo 128 and exo 124 N-Gly
epoxides were synthesized (Scheme 38).
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Scheme 38- Synthesis of 5,6-epoxy-N-Gly-1,4-dimethylnorcantharimide
Based on established methods64 and our work, N-glycinylmaleimide 128 was synthesized and
underwent the expected Diels-Alder reaction with furan 82. The 48:52 endo:exo mixture
underwent epoxidation with mCPBA and the resulting epoxides were resolved by
chromatography to afford novel analogues 124 and 129. This newly established method will be
applied in the synthesis of analogues 125-127 (Figure 15) for subsequent testing by our
collaborator Dr. Michael Gleghorn.
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Chapter 2- New Methodology Studies for Access to 9-Membered
Lactones
3- Diels-Alder reactions of 2-methylene-cyclohexane-1,3-dione
3.1- Natural Products bearing 9-membered lactones
The proposed Diels-Alder reaction system may provide access to 9-membered lactones.
9-membered rings are a formidable challenge in many synthetic endeavors, especially in NP
synthesis. For example, several classes of medium sized lactones have been reported that feature
9-membered lactone moieties (Figure 16)66,67,68,69.

Figure 16- Natural products bearing a 9-membered lactone or similar entity (refs. embedded).
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3.2- Proposed Route to 9-membered Lactones
We anticipated the methylene dione 116 will participate in a Diels-Alder reaction with
2,5-dimethylfuran and the corresponding product can undergo an intramolecular cyclization
process (Scheme 39).

Scheme 39- (a)- Proposed synthetic route to 9 membered lactones. (b)- Proposed mechanism.
The proposed mechanism begins with an enolization of the Diels-Alder adduct 118. The
presence of the bicyclic ether as a β-leaving group could facilitate a fragmentation and ketene
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formation process. Following attack from the freed alkoxy moiety and tautomerization a 9membered lactone may be formed in one pot from the starting Diels-Alder adduct 118.

Scheme 40- Previous reports of Diels-Alder reactions of reactive intermediate 116 (top:
Hoffmann and Koser70) (bottom: Wei et al71)
The reactive methylene species 116 has been reported in the synthesis of terpenoid
natural products70, 71 (Scheme 40). Both reports detail the in situ generation of the reactive
methylene species 116 that undergoes a reverse-electron demand Diels-Alder reaction with an
electron rich alkene70, 71. To our knowledge, no studies have been reported on the use of 116 as a
dienophile in a normal-electron-demand Diels-Alder reaction.
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3.2.1- Hoffman and Koser Conditions

Scheme 41- Formation of Michael adduct 24 from reactive intermediate 20.
The literature described was applied to produce a normal-electron demand Diels-Alder
reaction of 2,5-dimethylfuran and the reactive methylene species 116 (Scheme 41). Under
Hoffman and Koser conditions70, dione 115 was added in one portion to a solution of catalytic
NaOAc, 2eq of 2,5-dimethylfuran (82) and 2eq of paraformaldehyde with 4A molecular sieves
suspended in AcOH. We believe the use of paraformaldehyde was done by the authors for a
controlled release of formaldehyde monomers and by extension controlled formation of
methylene species 116. The crude product showed significant product formation in GCMS and
was subsequently reduced for purification (Scheme 42). Upon in situ formation, the reactive
intermediate rapidly undergoes a Michael addition to adduct 120 (Scheme 41). The Michael
adduct 120 was identified by GCMS (m/z=236) with a fragmentation pattern that matched the
available spectrum from SDBS.
Exhaustive chromatographic purification efforts failed to produce pure reduced adduct
118. Under the same conditions, an excess of furan was employed (10eq) but did not yield a
significant increase in desired Diels-Alder adduct 117 formation compared to byproducts. An
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increased reaction duration (4 days) failed to improve the formation of the Diels-Alder adduct
117 relative to the Michael adduct 120. Increased heat (90°C, 24hrs) caused decomposition of
starting reagents. It was determined that tandem chromatographic purifications were necessary.

Scheme 42- Diels-Alder synthesis of 21 and reduction under Hoffman and Koser conditions.
A multigram scale reaction for 117 was prepared under the described conditions
(time=7hr) and reduced to adduct 118 (Scheme 42). It was discovered that a significant portion
of byproducts in crude oil 118 could be removed by suspension in hexanes. The resulting solids
were further purified by column chromatography, yielding adduct 118 of an acceptable purity
(6% yield from 115). Further purification was performed by radial chromatography giving a pure
sample of 118 (<1% from 115) as a colorless oil. The physical properties (BP=40°C) and
diminished mass returns was cause for concern as product may be lost during solvent removal
under reduced pressure.
We could not verify the structure of pure 118 by conventional 1HNMR due to the
complexity of the molecule, noting its 14 magnetically inequivalent protons. The resulting
spectra is a large collection of overlapping peaks. However, the signals appear in appropriate
shift ranges. A conventional 13C CPD showed two signals from 195-200ppm a plausible region
for the carbonyl carbons of 118. The remaining signals appeared in appropriate ranges for all
other carbons. A 13C DEPT 135 experiment showed only two peaks in the positive region,
corresponding to the two methyl groups of 118. The cumulative NMR data, a pure
chromatogram (m/z=222) in GCMS with an agreeing fragmentation pattern, strongly suggest the
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successful formation and isolation of the Diels-Alder adduct 118. Efforts to improve yield and
purification methods were then investigated under Wei conditions.
3.2.2- Wei Conditions

Scheme 43- Synthesis of adduct 21 under Wei conditions.
Initially, Wei conditions (Scheme 43) gave crude product mixtures that contained
significantly fewer by-products in comparison to Hoffmann and Koser conditions70. This
prompted further optimization efforts of these conditions to produce Diels-Alder product 117.
Upon reaction completion, the reaction layer is diluted with water and the organic
products are extracted. It was discovered the yield is greatly affected by the extraction solvent.
Extraction with Et2O returned only Michael adduct 120, which demonstrates a way to remove
the undesired byproduct before chromatographic purification. Extraction with ethyl acetate
returns a mixture that contains mostly Michael adduct 120 but an appreciable amount of desired
Diels-Alder adduct 117 is extracted. Extraction with DCM gave a 1:1 mixture of 120 and 117.
Extraction with CHCl3 gave a crude sample with 117 as the major component. It was concluded
that more polar extraction solvents greatly increase yields of desired compound 117. Reduction
of the crude oil 117 extracted with chloroform generated crude adduct 118 with significantly
fewer byproducts than under Hoffman and Koser conditions, eliminating the need for the
preliminary column chromatography purification. Due to the possibility of product loss during
solvent removal, the use of a volatile eluent was employed so it could more easily be removed
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without exceptionally low pressures. Purification of the crude adduct 118 by radial
chromatography eluted with pure Et2O to afford pure adduct 118 was achieved in a 50%
recovery of the material loaded.
3.3- Testing Appropriate Base for Synthesis of Lactone 119

Scheme 44- Treatment of reduced adduct 118 to promote ketene formation and intramolecular
lactonization.
Before extensive purification efforts for 118, partially purified portions from crude
reactions under Hoffman and Koser conditions were subjected to treatment with t-BuONa and
NaH (Scheme 44). Treating 118 with t-BuONa or an excess of NaH produced no detectable
change in the crude mixture composition. It was discovered based on computer simulation
(courtesy of D. Tusch) that the dimethyl substituents of 118 impart significant steric hindrance in
the approach of a base72. This prompted investigation for synthesis of the demethylated
counterpart 121 and its role as a precursor in the transformation to lactone 123 (Scheme 45).
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3.4- Synthesis of Demethylated Precursor 121

Scheme 45- Investigation of demethylated analogue 121 as a precursor to lactone 123.
Both Hoffmann and Wei conditions were applied in the synthesis of 121. Attempts to reduce
Diels-Alder adduct 121 gave GCMS data that suggests reduction under our precedented
conditions is not chemoselective and reduction of the carbonyl occurs as in 122. As a result,
adduct 121 was treated with NaH and NaNH2 which did not produce lactone 123 in detectable
amounts. However, Diels-Alder adduct 121 was consumed in treatment with both NaH and
NaNH2 according to GCMS analysis. In future work, the unknown products produced from the
treatment of 121 with NaH and NaNH2 will be isolated and characterized.
3.5- Conclusions and Future Work
Access to a 9-membered lactone was investigated via the Diels-Alder reaction of in situ
generated 2-methylene-cyclohex-1,3 dione (116) with 2,5-dimethylfuran (82) and furan (8). It
was found that Diels-Alder adduct 118 can be isolated by a tandem chromatographic purification
procedure. The extremely poor yields of the current process require optimization studies of the
current reaction system. Considerable improvements were made in the synthesis of Diels-Alder
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adduct 118 under Wei conditions. Extraction with polar solvents allowed for better isolation of
the Diels-Alder adduct 117. The Michael adduct 120 can be removed from the crude product by
washing with Et2O. The use of volatile solvent systems in chromatographic purification has been
shown to improve recovery rates. Further studies will be identifying the appropriate conditions to
reduce the alkene moiety of 121 without simultaneous reduction of its carbonyl. Additional work
necessary will be to isolate and characterize products of base treatments of 121.
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General Procedures
All non-aqueous reactions were performed in flame- or oven-dried (125 °C) glassware
under normal atmosphere and stirred magnetically, unless otherwise specified. Reaction
temperatures other than room temperature were performed in baths (ice/water for 0 °C), and a
heating mantle regulated by a variable autotransformer for temperatures greater than room
temperature or a sand bath heating on a hot plate with external temperature monitoring. The
phrases “concentrated in vacuo”, “concentrated under reduced pressure”, or “concentrated” refer
to removal of solvent via Büchi R-3 or R-210 rotary evaporator fit with Buchi V-700 or Buchi
V-100 vacuum.

Reagents and Solvents
Deionized water was used for all aqueous reactions, work-up procedures, and for the
preparation of aqueous solutions. All commercially available reagents and solvents were used as
obtained from the supplier without further purification unless otherwise noted below:
Dry dichloromethane- dried by reaction with calcium hydride and distilled under ambient
pressure
Dry tetrahydrofuran- dried by reaction with sodium metal in the presence of
benzophenone indicator and distilled under ambient pressure

Chromatography
The phrases “column chromatography”, “chromatography” or “chromatographic
purification” refer to flash column chromatography using 230-400 mesh silica gel (SiliaFlash®)
and standard techniques. The phrase “radial chromatography,” refers to purification on a
Centrifugal Thin-Layer Chromatograph Model 7924T-01 device using standard techniques.
Analytical thin-layer chromatography (TLC) was performed on pre-coated silica gel 60 F254
74

aluminum backed plates (Macron). Visualization was affected by short-wave (254 nm) UV
illumination, and/or placing the plate in an iodine chamber for 15-30 seconds and then using a
heat-gun to remove the iodine, and/or by dipping the plate in a stain solution and heating with a
heat-gun for 10-15 seconds when appropriate. Stain solutions were prepared as follows:
Potassium permanganate: 3 g potassium permanganate, 20 g potassium carbonate, and 5
mL of 5% w/w sodium hydroxide in 300 mL water
p-Anisaldehyde: 15 mL p-anisaldehyde and 2.5 mL conc. sulfuric acid in 250 mL ethanol

Physical Data
Proton nuclear magnetic resonance (1H-NMR) spectra were obtained on a Bruker DRX300 (300.13MHz) or Avance III 500 (500.13 MHz) nuclear magnetic resonance spectrometer.
Chemical shifts are reported in ppm (δ) relative to internally referenced solvent residual peak
using CDCl3 as solvent (7.26 ppm), unless otherwise specified. 1H-NMR Data are reported as
follows: chemical shift (multiplicity, coupling constants in Hz, number of protons)./?
Multiplicities are abbreviated as follows: s (singlet), d (doublet), t (triplet), q (quartet), dd
(doublet of doublets), m (multiplet and/or multiple resonances), br s (broad singlet), br d (broad
doublet).
Carbon nuclear magnetic resonance (13C-NMR) spectra were obtained on a Bruker DRX300 (75.48 MHz) or Avance III 500 (125.77 MHz) nuclear magnetic resonance spectrometer.
Chemical shifts are reported in ppm (δ) relative to internally referenced solvent residual peak
using CDCl3 as solvent (77.16 ppm), unless otherwise specified.
Fourier-transform infrared (FT-IR) spectra were recorded using ATR on a Shimadzu
IRAffinity-1 FT-IR and are reported in wavenumbers (cm-1).
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Low-resolution mass spectra were obtained using a Hewlett Packard 6890 Series gas
chromatograph with a 5973 Mass Selective Detector using electron impact (EI) methods and
dichloromethane, ethyl acetate, methanol or diethyl ether as the sample solvent. Additional lowresolution mass spectra were obtained on a Shimadzu LCMS-2020 ultra-high-performance-liquid
chromatograph equipped with photo-diode array detector and Quadrupole mass spectrometer
using electrospray ionization (ESI) methods with methanol, or ethyl acetate as the sample
solvent.

Theoretical Data
All in silico experiments were conducted using PyRx Virtual Screening Tool docking
simulator software. All ligands used in docking systems were drawn using Avagadro molecular
modeling software. Simulations performed were on the 2q7i active site of the wild-type androgen
receptor structure as reported from RCSB Protein Data Bank. Testosterone was removed from
the active site using PyMol Moleular Visualization software.
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Experimentals

exo-1,4-dimethyl-7-oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid anhydride (83)

To a solution of maleic anhydride (251.8mg, 2.57mmol) in EtOAc (1mL) was added 2,5dimethylfuran (0.25mL, 0.2348mmol) and stirred at RT. After 48hrs, the solvent was removed in
vacuo yielding a while solid. The crude solid was assayed by NMR in CDCl3 and determined to
be a 1:1 mixture of 15 and 83 (50% conversion by 1HNMR integration) and unreacted 2,5dimethylfuran 82.

1

HNMR (300MHz, CDCl3): Compound 83 δ 6.351 (s, 2H) 3.163 (s, 2H) 1.763 (s, 6H)

Compound 15 δ 7.038 (s, 2H) Compound 82 δ 5.822 (s, 2H) 2.239 (s, 6H) in agreement with
previous reports48,59.
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exo-1,4-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid anhydride (84)

The unpurified adduct 83 (122.4mg) was dissolved in EtOAc (2mL) and degassed under
vacuum and placed under N2. 5% wet Pd/C (49.2mg, cat.) was added to the solution and
degassed under vacuum and placed under N2. H2 was introduced with a balloon and the
heterogenous mixture was stirred at RT. After 1hr, H2 was removed from the vessel under
vacuum and the mixture was filtered through celite, washed with EtOAc (3x 20mL) and
concentrated in vacuo yielding a white solid. The crude solid was assayed by NMR and
determined to be a mixture of 84 (45%) and anhydride 85 (55%).

1

HNMR (300MHz, CDCl3): Compound 84 δ 3.145 (s, 2H) 2.020 (s, 4H) 1.604 (s, 6H)

Compound 85 δ 2.991 (s, 4H) in agreement with previous reports48,59.
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exo-1,4-dimethyl-7-oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxy-(N-methyl)imide (58)
endo-1,4-dimethyl-7-oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxy-(N-methyl)imide (87)

EtOAC, RT, 24hrs: To a stirred solution of maleimide 86 (270mg, 2.81mmol) in EtOAc
(1mL) was added furan 83 (0.26g, 2.70mmol) and stirred at RT. After 24hrs the solvent was
removed in vacuo to give a white solid which was purified via gradient flash chromatography
(25% EtOAc/Hexanes → 100% EtOAc) yielding pure exo 58 and endo 87 adducts as white
solids.

1

HNMR (300MHz, CDCl3): Compound 58 δ 6.302 (s, 2H) 2.959 (s, 3H) 2.831 (s, 2H) 1.706 (s,

6H) Compound 87 δ 6.192 (s, 2H) 3.226 (s, 2H) 2.803 (s, 3H) 1.780 (s, 6H) in agreement with a
previous report58.
Solvent studies performed (Table 3, entries 1-3) employed identical conditions but Et2O
and DCM were substituted for EtOAc and resulting endo:exo ratios were determined by 1HNMR
integration.
EtOAC, reflux, 24hrs: To solution of maleimide 86 (260mg, 2.34mmol) in EtOAc
(1mL) was added 2,5-dimethylfuran (0.25mL, 2.34mmol) and heated to reflux in sand bath with
external temp monitoring, then stirred at reflux for 24hrs. An aliquot of the reaction mixture was
removed, concentrated in vacuo and assayed for endo/exo composition by 1HNMR integration.
82

For time study: To solution of maleimide 86 (260mg, 2.34mmol) in EtOAc (1mL) was
added 2,5-dimethylfuran (0.28mL, 2.37mmol) and stirred at reflux for 96hrs. An aliquot of the
reaction mixture was removed, concentrated in vacuo and assayed for endo/exo composition by
1

HNMR integration.
Boric acid catalyzed: Maleimide 86 (100mg, 1.02mmol) and boric acid (21.4mg,

0.346mmol) were dissolved in 1mL of 1,4-dioxane and stirred. 2,5-dimethylfuran was added
(0.114mL, 1.07mmol) and the flask was heated to reflux for 3hrs. An aliquot of the reaction
mixture was removed, concentrated in vacuo and assayed for endo/exo composition by 1HNMR
integration.
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exo-1,4-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxy-(N-methyl)imide (88)
endo-1,4-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxy-(N-methyl)imide (89)

In separate round bottom flasks, Diels-Alder adducts 58 (250mg, 1.29mmol) and 87
(340mg, 1.75mmol) were dissolved in 3:1EtOAc (16.5mL) and the mixtures were degassed by
vacuum and placed under N2. 5% wet Pd/C was added (559.3mg, cat.) was added to each flask
which were degassed by vacuum and placed under N2. H2 (g) was introduced with a balloon. The
mixtures were stirred at RT for 4hr then degassed by vacuum, filtered through celite and washed
with EtOAc (3x 20 mL). The solvent was removed in vacuo yielding both reduced products 88
and 89.
Compound 88
1

HNMR (300MHz, CDCl3): δ 2.950 (s, 4H) 2.853 (s, 3H) 1.753 (s, 4H) 1.591 (s, 6H)
CNMR (126MHz, CDCl3): δ 176.22; 85.16; 53.66; 38.13; 25.02; 18.16

13

MS (EI): Calcd. For C11H15NO3 [M=] = 209, found = 209
IR (neat, cm-1): 2987, 2939, 2875, 2252, 1697, 1435, 1384, 1286, 1246
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Compound 89
1

HNMR (300MHz, CDCl3): δ 3.162 (s, 2H) 2.967 (s, 3H) 1.679 (s, 4H) 1.672 (s, 6H)
CNMR (126MHz, CDCl3): δ 176.07; 86.10; 57.29; 33.67; 24.79; 21.50

13

MS (EI): Calcd. For C11H15NO3 [M=] = 209, found = 209
IR (neat, cm-1): 2974, 2931, 2885, 2252, 1697, 1429, 1379, 1336, 1288

85

N-phenylmaleimide (90)

Anhydride 15 (5g, 50.99mmol) was dissolved in Et2O (62.5mL) and stirred at RT. A
solution of aniline (4.655mL, 50.99mmol) in Et2O (12.5mL) was added dropwise through an
addition funnel. The resulting yellow slurry was stirred at RT for 1hr then was cooled to 0°C and
the solids were filtered and dried in vacuo. The intermediary yellow solid was added to a
solution of NaOAc (1.65g, 3.96mmol) in Ac2O (16.75mL), stirred and heated to 100°C for 30
min. The solution was cooled to 0°C, poured into ice cold water (200mL) and stirred vigorously
for 30min. The precipitate was filtered, washed with ice cold water (3x 75mL), air-dried, then
taken up in hot cyclohexane. The undissolved solids were filtered away and the filtrate was
concentrated in vacuo to yield maleimide 90 (24%).

1

HNMR (300MHz, CDCl3): 7.389 (m, 5H) 6.872 (s, 2H) in agreement with known spectrum73.
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N-benzylmaleimide (93)

To a solution of anhydride 15 (5.00g, 50.99mmol) in Et2O (67mL) was added a solution
of benzylamine (5.465g, 51.00mmol) in Et2O (25mL) dropwise through an addition funnel over
30min. The resulting slurry was stirred for 1hr then filtered and air dried. The recovered solids
were added to a suspension of NaOAc (2.67g, 32.55mmol) in Ac2O (19mL) and heated to 100°C
for 30min. The resulting solution was poured into ice cold water (125mL) and stirred vigorously
for 30min. The precipitate was filtered and purified by recrystallization over 2:1 EtOH:H2O to
afford maleimide 93 (49%).

1

HNMR (300MHz, CDCl3): 7.313 (m, 5H) 6.704 (s, 2H) 4.673 (s, 2H) in agreement with a

previous report74.
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exo-1,4-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxy-(N-phenyl)imide (91)
endo-1,4-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxy-(N-phenyl)imide (92)

To a solution of N-phenylmaleimide 90 (1.35g, 7.80mmol) in EtOAc (10mL) was added
furan 82 (0.926mL, 8.58mmol) and stirred at RT. After 96hrs the solvent was removed in vacuo
and isomers were resolved by gradient flash chromatography (25% EtOAc/Hex → 100% EtOAc)
affording pure exo 91 and endo 92 adducts as white solids (53% yield, endo:exo 80:30).

1

HNMR (300MHz, CDCl3): Compound 91 δ 7.408 (m, 5H) 6.369 (s, 2H) 2.990 (s, 2H) 2.207 (s,

6H) Compound 92 δ 7.387 (m, 4H) 7.131 (s, 1H) 7.106 (s, 1H) 6.360 (s, 2H) 3.385 (s, 2H) 1.843
(s, 6H) in agreement with a previous report57.
Boric acid catalyzed: To a solution of N-phenylmaleimide 90 (200mg, 1.15mmol) and
boric acid (26.0mg, 42.0mg) in 1,4-dioxane (5mL) was added 2,5-dimethylfuran (0.114mL,
1.21mmol), stirred and heated to reflux for 3hrs. An aliquot of the reaction mixture was
removed, concentrated in vacuo and assayed for endo/exo composition by 1HNMR integration.
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exo-1,4-dimethyl-7-oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxy-(N-benzyl)imide (94)
endo-1,4-dimethyl-7-oxabicyclo[2.2.1]hept-5-ene-2,3-dicarboxy-(N-benzyl)imide (95)

To a solution of maleimide 93 (1.5730g, 8.42mmol) in EtOAc (4mL) was added furan 82
(1.00mL, 9.26mmol) and stirred at RT. After 24hrs the solvent was removed in vacuo and
isomers were resolved by gradient flash chromatography (20% EtOAc/Hex → 100% EtOAc)
affording pure exo 94 adduct as a pale yellow oil and endo 95 adduct as a white solid (90% yield,
endo:exo 77:23).
Compound 94
1

HNMR (300MHz, CDCl3): δ 7.303 (m, 5H) 6.305 (s, 2H) 4.647 (s, 2H) 2.835 (s, 2H) 1.695 (s,

6H)
CNMR (126MHz, CDCl3): δ 174.43; 140.83; 128.52; 127.80; 127.56; 87.58; 52.88; 42.14;

13

15.84
IR (neat, cm-1): 3066, 3034, 2987, 2981, 2935, 2358, 2335, 2252, 1697, 1386, 1342, 1178, 1109
Compound 95
1

HNMR (300MHz, CDCl3): δ 7.292 (m, 5H) 5.926 (s, 2H) 4.467 (s, 2H) 3.212 (s, 2H) 3.385 (s,

2H) 1.760 (s, 6H)
CNMR (126MHz, CDCl3): δ 174.83; 140.95, 189.08; 128.47, 127.96, 88.01, 53.40, 42.23;

13

18.65
89

IR (neat, cm-1): 3086, 3034, 2978, 2933, 2360, 2341, 1695, 1392, 1340, 1188, 1085

90

exo-5,6-dibromo-1,4-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid anhydride
(98)
DA adduct 83 (1.00g, 5.15mmol) was dissolved in dry DCM (25mL) in an oven dried
RBF and stirred magnetically. The flask was purged and placed under N2 and Br2 was added
dropwise via syringe. After 7hrs the mixture was quenched with sodium thiosulfate, diluted with
DCM, washed with brine (2x 100mL) and the organic layer was concentrated in vacuo affording
a brown solid (86%) that was used without further purification.

1

HNMR (300MHz, acetone-d6): Internally referenced using solvent residual peak (2.05ppm) δ

4.508 (dd, J = 4.2Hz, 4.2Hz, 2H) 4.318 (dd, J = 7.5Hz, 6.0Hz, 2H) 1.640 (s, 3H) 1.605 (s, 3H) in
agreement with a previous report75.

91

exo-5,6-epoxy-1,4-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxy-(N-phenyl)imide
(101)

To a solution of Diels-Alder adduct 91 (160mg, 0.594mmol) in EtOAc (6mL) was added
mCPBA (205mg, 1.19mmol) and stirred at RT until a precipitate was observed, which was
filtered and washed with cold diethyl ether (2x 30mL) yielding pure epoxy adduct 101 (94%).

1

HNMR (300MHz, CDCl3): δ 7.450 (m, 5H) 3.402 (s, 2H) 3.305 (s, 2H) 1.689 (s, 2H)
CNMR (126MHz, CDCl3): δ 173.32; 129.32; 129.00; 126.64; 83.63; 55.15; 51.74; 14.17

13

MS (EI): Calcd. For C16H15NO4 [M=] = 285, found = 285
IR (neat, cm-1): 3082, 3032, 2980, 2933, 2358, 2337, 2252, 1699, 1392, 1168
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endo-5,6-epoxy-1,4-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxy-(N-phenyl)imide
(102)
To a solution of Diels-Alder adduct 91 (308mg, 0.159mmol) in EtOAc (8mL) was added
mCPBA (547.5mg, 0.317mmol) and stirred at RT for 120hr. The mixture was diluted with
EtOAc (25mL) and washed (5x 15mL) with 50% NaHCO3 (aq), brine (1x 25mL), dried (Na2SO4)
filtered and the filtrate was concentrated in vacuo. The resulting white solid was purified via
gradient flash chromatography (25% EtOAc/Hexanes → 100% EtOAc) affording epoxide 102 as
a white power (83%).

1

HNMR (300MHz, CDCl3): δ 7.441 (m, 3H) 7.210 (m, 2H) 3.409 (s, 2H) 3.364 (s, 2H) 1.764 (s,

6H)
CNMR (126MHz, CDCl3): δ 174.13; 169.48; 129.11; 129.11; 127.93; 126.04; 83.55; 55.95;

13

50.98; 16.93
MS (EI): Calcd. For C16H15NO4 [M=] = 285, found = 285
IR (neat, cm-1): 3099, 3068, 2990, 2931, 1707, 1597, 1500 1381, 1182, 1145
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endo-5,6-epoxy-1,4-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxy-(N-benzyl)imide
(103)
To a solution of Diels-Alder adduct 95 (390mg, 1.37mmol) in EtOAc (10mL) was added
mCPBA (475mg, 2.75mmol) and stirred at RT for 240hr. The mixture was diluted with EtOAc
(50mL) and washed (10x 20mL) with 50% NaHCO3 (aq), dried (Na2SO4), filtered and
concentrated in vacuo affording a white solid (92%) of acceptable purity.

1

HNMR (300MHz, CDCl3): δ 7.453 (m, 5H) 4.581 (s, 2H) 3.167 (s, 2H) 2.184 (s, 2H) 1.646 (s,

6H)
CNMR (126MHz, CDCl3): δ 173.70; 129.13; 128.72; 128.40; 83.86; 55.93; 50.87; 42.67; 16.84

13

MS (EI): Calcd. For C17H17NO4 [M=] = 299, found = 299
IR (neat, cm-1): 3064, 3034, 2357, 2324, 2260, 1697, 1433, 1388, 1342, 1311, 1168

94

exo-1,4-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxy-(N-benzyl)imide (100)

To a solution of maleic anhydride 15 (1.05g, 10.70mmol) in EtOAc (10mL) was added
2,5-dimethylfuran (1.27mL, 11.78mmol) and stirred at RT. After 48hrs the reaction mix was
diluted with EtOAc (20mL) and 5% wet Pd/C was added (450mg, cat.). The mixture was
degassed by vacuum and placed under N2. H2 (g) was introduced with a balloon and stirred
vigorously at RT for 20hrs. The mixture was filtered through celite and washed (3x 30mL) with
EtOAc. The filtrate was concentrated in vacuo yielding a mixture of reduced adduct 84 and
reduced anhydride 85 by comparison with previous NMR data. A portion of the crude mixture
(500mg) was added to a stirred solution of triethylamine (1.24mL, 8.91mmol) in toluene
(12.7mL) in a three neck RBF equipped with a reflux condenser. Benzylamine (0.28mL,
2.55mmol) was added dropwise and the mixture was heated to reflux overnight. The resulting
solids were filtered, and the filtrate was diluted with EtOAc (30mL) and sat. NaHCO3 (10mL)
then washed with water (20mL), brine (50mL) and the organic layer was concentrated in vacuo.
The resulting solids were purified by gradient flash chromatography (15% EtOAc/Hex → 100%
EtOAc) affording compound 100 as a white solid (16% overall).

1

HNMR (300MHz, CDCl3): δ 7.301 (m, 5H) 4.634 (s, 2H) 2.848 (s, 2H) 1.742 (s, 4H) 1.568 (s,

6H)
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CNMR (126MHz, CDCl3): δ 173.70; 129.13; 128.72; 128.40; 83.86; 55.93; 50.87; 42.67; 16.84

13

MS (EI): Calcd. For C17H17NO4 [M=] = 299, found = 299
IR (neat, cm-1): 3064, 3034, 2357, 2324, 2260, 1697, 1433, 1388, 1342, 1311, 1168
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exo-1,4-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxy-(N-glycinyl)imide (100)

Anhydride 15 (5.00g, 50.99mmol) and glycine (3.80g, 50.61mmol) were dissolved in
AcOH (80mL) and stirred at RT for 6hrs. The intermediary white solid was filtered and purified
by recrystallization over MeOH. The purified intermediate was suspended in a solution of
triethylamine (5mL, 35.87mmol) in toluene (110mL). The reaction vessel was equipped with a
Dean-Stark apparatus and heated to reflux for 1.5hrs. The mixture was concentrated in vacuo and
the residual solids were acidified with 3M HCl and extracted with EtOAc (3x 50mL). The
organic layers were combined, washed with brine (50mL), dried (Na2SO4), filtered and
concentrated in vacuo yielding an orange hygroscopic solid (1.24g). A portion of the solid
(640mg) was dissolved in EtOAc (5mL) and 2,5-dimethylfuran (0.47mL) was added and the
mixture was stirred at RT for 24hrs. The solvent was removed in vacuo and the crude product
was dissolved in EtOAc (80mL) and combined with 5% wet Pd/C (1.00g, cat.). H2 (g) was
introduced with a balloon and the mixture was stirred vigorously for 7hr. The reaction mix was
filtered through celite, rinsed with EtOAc (3x 50mL) and concentrated in vacuo yielding crude
111 as an off-white solid (0.4g, 3% overall). Purification and full characterization of 111 is in
progress by a current Cody group member.
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exo-1,4-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxy-(N-L-tryptophanyl)imide (113)

To a solution of L-tryptophan (5.00g, 24.48mmol) in AcOH (30mL) was added a solution
of maleic anhydride (2.40g, 24.47mmol) in AcOH (10mL). The resulting yellow slurry was
stirred at RT overnight (17hr), then the solvent was removed in vacuo yielding a glutinous
orange solid that was taken up in THF and added to a solution of Et3N (5mL) in toluene (500mL)
in a 1L RBF equipped with a reflux condenser and Dean-Stark apparatus. The mixture was
stirred at reflux for 3hrs, then cooled to RT and concentrated in vacuo. The crude solid was
acidified with 2M HCl (100mL) and extracted with EtOAc (3x 100mL), dried (Na2SO4) and
concentrated in vacuo yielding crude maleimide 112 of acceptable purity. The crude oil 112
(2.37g, 8.34mmol) was taken up in CHCl3 (10mL) and 1mL (9.26mmol) of 2,5-dimethylfuran
was added. The reaction mixture was stirred for 72hrs and assayed regularly by 1HNMR,
indicating endo/exo equilibrium was achieved after 2hrs. The reaction mix was concentrated in
vacuo yielding Diels-Alder adduct 113 as a mixture of endo:exo iosmers (23% overall, endo:exo
83:17). Small portions of the crude mixture were used in attempts to resolve isomers that were
unsuccessful. A representative sample of a purified endo/exo mixture (35:65) was used for
characterization of Diels-Alder product 113.

98

1

HNMR (500MHz, CDCl3): δ 9.450 (br s, 1H) 8.105 (s, 1H) 8.067 (s, 1H) (7.577, d, 1H, J =

8Hz) (7.510, d, 1H, J = 7.5Hz) 7.339-7.295 (m) 7.187-7.094, (m) 6.993 (s, 1H) 6.989 (s, 1H)
6.224 (m, 2H) 5.582 (m, 2H) 5.142 (m, 2H) 5.121 (m, 2H) 3.611 (m, 2H, 2H) 3.022 (dd, J =
8Hz, 8Hz) 2.670 (dd, J = 7Hz, 7Hz) 1.674 (s, 3H) 1.646 (s, 3H) 1.624 (s, 3H) 1.318 (s, 3H).
CNMR (126MHz, CDCl3): δ 177.34; 174.54; 174.31; 173.84; 173.67; 170.04; 141.25; 140.80;

13

137.74; 136.33; 134.16; 127.55; 127.16; 122.83; 122.41; 122.16; 119.82; 118.65; 111.35;
110.76; 110.28; 87.78; 53.58; 53.44; 52.88; 52.75; 52.58; 52.02
IR (neat, cm-1): 3419, 3041, 2935, 2252, 1771, 1699, 1389, 1354, 1281, 1234, 1180, 1096, 910
MS (ESI-): Calcd. For C21H20N2O5 [M=] = 380, ESI- found [M-1] = 379
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rac-1,4-dimethyl-oxabicyclo[2.2.1]-spiro[5,5]-7,11-dioxo-undecane (118)

Paraformaldehyde (1.0712g, 35.55mmol), NaOAc (0.1464g, 1.785mmol), 2,5dimethylfuran (3.84mL, 35.55mmol) and 4g of 4A° mol. sieve powder were combined and
stirred in AcOH (15mL). 1,3-cyclohexanedione (2.00g, 17.84mmol) was added in one portion,
the flask was equipped with a reflux condenser and heated to 60°C with a sand bath with external
temp. monitoring and the mixture was stirred vigorously for 5 hours. The flask was cooled to
RT, diluted with DCM (100mL), filtered through celite, which was rinsed with DCM (2x 80mL).
The organic layer was transferred to a 1L separatory funnel, washed with sat. NaHCO3 (aq) (2x
80mL) then H2O (1x 100mL), brine (1x 100mL), then dried (Na2SO4), filtered and concentrated
in vacuo yielding a crude oil. The crude oil was taken up in EtOAc (200mL) and degassed,
placed under N2 and wet Pd/C (5%wt., 8.00g, cat.) was added. The mixture was degassed and H2
was introduced with a balloon. The mixture was stirred vigorously under H2 (g) overnight (24hrs)
then purged, filtered through celite which was rinsed with EtOAc (2x 100mL) and concentrated
in vacuo. The crude oil was purified by gradient chromatography (25% EtOAc/Hex → 100%
EtOAc) then further by radial chromatography (50% EtOAc/Hex) yielding pure 118 as a
colorless oil (<1%).
1

HNMR (500MHz, CDCl3): Unresolved.
CNMR (126MHz, CDCl3): δ 168.30; 167.52; 112.13; 98.67; 38.42; 37.43; 36.79; .36.15; 29.10;

13

28.57; 25.37; 23.01; 20.97

100

MS (EI): Calcd. For C13H13.O3 [M=] = 222, found = 222
IR (neat, cm-1): 2957, 2932, 2872, 2360, 2330, 1618, 1514, 1333, 1195, 910
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exo-5,6-epoxy-1,4-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxy-(N-glycinyl)imide
(124)
endo-5,6-epoxy-1,4-dimethyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxy-(N-glycinyl)imide
(129)
Anhydride 15 (5g, 50.99mmol) and glycine (3.83g, 51.02mmol) were dissolved in AcOH
(80mL) and stirred at RT overnight (16hr). The solvent was removed in vacuo giving a white
powder, that was added to a solution of NEt3 (7mL) in toluene (500mL) in a 3-neck RBF
equipped with a reflux condenser and Dean-Stark trap, then heated to reflux for 3hrs. The flask
was cooled to RT and the solvent was removed in vacuo. The residual glutinous solids were
taken up in 2M HCl (300mL) and extracted with EtOAc (3x 100mL), dried (MgSO4), filtered
and concentrated in vacuo yielding intermediary maleimide 128 as an orange solid that was used
without further purification. The crude solids (3.84g, 24.76mmol) were dissolved in EtOAc
(50mL) and furan 82 was added (3.00mL, 27.77mmol) and stirred at RT. After 24hrs, a
precipitate had accumulated in the flask. The flask was cooled to 4°C in a fridge for 30min, and
the precipitate was filtered, washed with cold EtOAc (3x 25mL) and identified as the endo DielsAlder product (1.04g, 23% of crude products). The filtrate was concentrated in vacuo yielding a
102

48:52 endo:exo mixture of Diels-Alder products (3.4097g, 77% of crude products). A portion of
the crude endo:exo mixture (1.47g, 5.84mmol) was suspended in EtOAc (50mL) and heated
gently to dissolve. mCPBA was added (2.11g, 12.22mmol) and stirred at RT for 96hrs. The
solvent was removed in vacuo and the crude epoxide products were resolved by gradient
chromatography (2:25:73 AcOH:EtOAc:Hex → 2:98:0 AcOH:EtOAc:Hex) yielding pure
epoxides 124 (0.25g, 3.7% from 15) and 129 (0.22g, 4.3% from 15).
Compound 124
1

HNMR (500MHz, DMSO-d6): Internally referenced using solvent residual peak (2.50ppm) δ

4.405 (s, 2H) 3.379 (s, 2H) 3.263 (s, 2H) 1.522 (s, 6H)
CNMR (126MHz, DMSO-d6): Internally referenced using solvent residual peak (39.51pm) δ

13

173.60; 82.34; 55.68; 51.07; 16.69
MS (ESI-): Calcd. For C12H13NO6 [M=] = 267, ESI- found [M-1] = 266
IR (neat, cm-1): 3136, 2985, 2935, 1745, 1681, 1431, 1328, 1165, 1115, 932, 869
Compound 129
1

HNMR (500MHz, DMSO-d6): Internally referenced using solvent residual peak (2.50ppm) δ

4.054 (s, 2H) 3.570 (s, 2H) 3.180 (s, 2H) 1.407 (s, 6H)
CNMR (126MHz, DMSO-d6): Internally referenced using solvent residual peak (39.51pm) δ

13

174.03; 167.83; 82.35; 54.18; 51.24; 13.72
MS (ESI-): Calcd. For C12H13NO6 [M=] = 267, ESI- found [M-1] = 266
IR (neat, cm-1): 3107, 2980, 2962, 1699, 1418, 1329, 1182, 934, 872
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Appendix: 1H-NMR, 13C-NMR, NOESY, COSY, GCMS and FT-IR Spectra
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